ライフサイエンスコーパス: antimetabolite

1 ine or systemic 2-deoxy-d-glucose (a glucose antimetabolite).

2 ly described cellular efflux system for this antimetabolite.

3 ed donor when it is added to or replaces the antimetabolite.

4 ding of TS degradation and its regulation by antimetabolites.

5 d pantothenate analogs are growth-inhibiting antimetabolites.

6 as comparable to that observed with specific antimetabolites.

7 il in high-risk patients, despite the use of antimetabolites.

8 the mechanistic classes except one class of antimetabolites.

9 nct from those of calcineurin antagonists or antimetabolites.

10 ompounds, including mTOR/PI3K inhibitors and antimetabolites.

11 unds, including 3 mTOR/PI3K inhibitors and 2 antimetabolites.

12 ary hypertension were less likely to receive antimetabolites.

13 oach and are being investigated as potential antimetabolites.

14 fety profile compared to trabeculectomy with antimetabolites.

15 for modulating activity of chemotherapeutic antimetabolites.

16 orticosteroids, cyclosporine, and the purine antimetabolites.

17 Treatment of cells with the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C)

18 The present studies demonstrate that the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C)

19 se-9, and (iv) induction of apoptosis by the antimetabolite, 1-beta-d-arabinofuranosylcytosine.

20 cluded calcineurin inhibitors (1295, 89.2%), antimetabolites (1205, 83%), corticosteroids, mammalian

21 tion and death were decreased by the glucose antimetabolite 2-deoxyglucose and increased by high bloo

22 se deprivation or treatment with the glucose antimetabolite 2-deoxyglucose caused nontransformed cell

23 naffected by food deprivation or MA, and the antimetabolite 2-DG has no impact on GAL in any area.

24 The energy antimetabolites 2-deoxy-D-glucose (2-DG) and Na-2-mercap

25 C), which is phosphorylated to the activated antimetabolite, 2'3'-dideoxycytidine triphosphate by cyt

26 raperitoneal (i.p.) injection of the glucose antimetabolite, 2-deoxy-D-glucose (2DG), or saline.

27 corticosteroids; 204 (41%) were treated with antimetabolites; 44 (9%) were treated with T cell inhibi

28 nd the loss of functional p53 signaling, the antimetabolite 5-fluorouracil (5-FU) failed to induce ar

29 The antimetabolite 5-fluorouracil (5-FU) is one of the most

30 s strikingly resistant to the effects of the antimetabolite 5-fluorouracil (5-FU), the mainstay of ad

31 The antimetabolite 5-fluorouracil (5FU) is a widely used che

32 HMG-CoA reductase inhibitor lovastatin, the antimetabolite 5-fluorouracil, and the cyclic nucleotide

33 racerebroventricular infusion of the glucose antimetabolite 5-thioglucose selectively promoted respon

34 use of antiscarring agents, particularly the antimetabolites 5-fluorouracil and mitomycin C, have rev

35 The cytotoxic antimetabolites, 5-flurouracil and mitomycin C both prol

36 ethyl-N'-nitro-N-nitrosoguanidine (MNNG) and antimetabolite 6-thioguanine (6-TG).

37 gnificant difference in treatment success by antimetabolite (80.4% for MTX compared to 64.1% for MMF;

38 lating agents or combination therapy with an antimetabolite, a biologic-response modifier, and cyclos

39 whether inhibition of Chk1 could potentiate antimetabolites, a mainstay of cancer therapy, which con

40 ermine more precisely the processes by which antimetabolites act as radiation sensitizers and to defi

41 protecting the tumour and allowing prolonged antimetabolite action.

42 emains unclear, especially in the context of antimetabolite adherence.

43 d for at least 1 year with infliximab and an antimetabolite agent experienced a relapse within 1 year

44 Hospitalized patients had their antimetabolite agent stopped.

45 We conducted similar analyses for other antimetabolite agents (e.g., azathioprine and mycophenol

46 The use of antimetabolite agents, such as mitomycin, has increased

47 s among the most efficacious and widely used antimetabolite agents.

48 Although the antimetabolites all target DNA replication, they differ

49 In the subgroup antimetabolite analysis, the addition of mitomycin C to

50 east 1 year with scheduled infliximab and an antimetabolite and had been in corticosteroid-free remis

51 reatment of pancreatic cancer using combined antimetabolite and sonodynamic therapy (SDT).

52 of combination chemotherapy consisting of 2 antimetabolites and a corticosteroid.

53 ective than medications in reducing IOP, and antimetabolites and B-radiation improve IOP control afte

54 d for disease modifying antirheumatic drugs, antimetabolites and biologic drugs.

55 g-term corticosteroid use include the use of antimetabolites and biological therapies.

56 Antimetabolites and calcineurin inhibitors were held or

57 eroids and immunosuppressive agents, such as antimetabolites and calcineurin inhibitors.

58 acid chemistry: coenzyme forms and function; antimetabolites and cancer chemotherapy.

59 The majority of patients treated with antimetabolites and corticosteroids were able to achieve

60 < .001), and in those who received intensive antimetabolites and glucocorticoids (P < .001).

61 atients on combined maintenance therapy with antimetabolites and identified factors associated with r

62 be used in conjunction with a combination of antimetabolites and rescue agents.

63 lt and is restricted to structurally similar antimetabolites and semi-synthetic analogues of their co

64 Some purine nucleoside antimetabolites and their monophosphate derivatives are

65 cted drug), 5-fluorouracil and methotrexate (antimetabolites), and vinblastine (a microtubule inhibit

66 tients were on tacrolimus and a mycophenolic antimetabolite, and 70% were on prednisone.

67 en combined with Thymoglobulin induction, an antimetabolite, and corticosteroids, TAC and CsA are com

68 received Thymoglobulin, corticosteroids, an antimetabolite, and cyclosporine monitored by C2 (n=50)

69 me, Ca(2+)-independence, resistance to an AA antimetabolite, and induction by another unsaturated fat

70 h antibody induction, calcineurin inhibitor, antimetabolite, and maintenance prednisone.

71 hat consisted of Thymoglobulin induction, an antimetabolite, and prednisone.

72 h antibody induction, calcineurin inhibitor, antimetabolite, and RDP versus historical controls treat

73 phosphorylation, whereas DNA-damaging drugs, antimetabolites, and alkylating agents do not.

74 cell killing using halogenated pyrimidines, antimetabolites, and other DNA-damaging agents or sensit

75 eated with DNA-damaging agents or nucleotide antimetabolites, and p53-deficient fibroblasts and Mdm2/

76 agents: including DNA cross-linking agents, antimetabolites, and topoisomerase I and II inhibitors.

77 lasses of drugs reviewed include alkylators, antimetabolites, anthracyclines, taxanes, camptothecins,

78 treated with low-dose glucocorticoids and an antimetabolite, anti-tumour necrosis factor (TNF) monocl

79 s systemic steroids, calcineurin inhibitors, antimetabolites, anti-tumor necrosis factor-alpha agents

80 ic utility as a modulator of the activity of antimetabolite antitumor agents by virtue of its inhibit

81 surgery using an infusion, optimal method of antimetabolites application, new adjustable sutures, and

82 ces among Medicare beneficiaries, a CNI plus antimetabolite approach led to improved outcomes.

83 Folates and folate antimetabolites are metabolically trapped in mammalian c

84 concern when powerful immune modulators and antimetabolites are used in combination, relatively few

85 ed signaling pathways, differences in use of antimetabolites as adjunctive therapy, tube material, an

86 Patients were enrolled in the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uvei

87 N, SETTING, AND PARTICIPANTS: The First-line Antimetabolites as Steroid-sparing Treatment (FAST) uvei

88 sis of patients with VKH from the First-line Antimetabolites as Steroid-sparing Treatment Uveitis Tri

89 nd identified raltitrexed, an antineoplastic antimetabolite, as the most potent PptT inhibitor yet re

90 nsored graft failure when managed with Tac + antimetabolite avoidance (adjusted hazard [aHR], 1.411.7

91 n that combines a depleting antibody with an antimetabolite, avoiding calcineurin inhibitors and ster

92 reading, scavenging of nutrients, removal of antimetabolites, balancing of metabolite pools, and esta

93 astic leukemia (ALL) were cured with limited antimetabolite-based chemotherapy regimens.

94 ving lower-risk leukemia and received mainly antimetabolite-based continuation therapy; the 130 cases

95 responses to therapy, should be treated with antimetabolite-based therapy designed to maintain their

96 for acute myeloid leukemia with monosomy 7; antimetabolite-based therapy for acute lymphoblastic leu

97 xtend these results to patients treated with antimetabolite-based therapy, we performed Southern blot

98 mproved survival among patients treated with antimetabolite-based therapy.

99 T-lineage ALL when treated with conventional antimetabolite-based therapy.

100 normality are best treated with conventional antimetabolite-based therapy.

101 een the substrate, allosteric regulator, and antimetabolite binding sites on pantothenate kinase and

102 ctural similarities to alkylating agents and antimetabolites, but which is non-cross-resistant with a

103 Antimetabolites +/- calcineurin inhibitors were held or

104 viously available immunosuppressives such as antimetabolites, calcineurin inhibitors, and alkylating

105 omparing patients exposed to TNF inhibitors, antimetabolites, calcineurin inhibitors, and alkylating

106 versus conventional immunosuppressive drugs (antimetabolites, calcineurin inhibitors, or both).

107 Bleb leaks after trabeculectomy with antimetabolites can be recalcitrant to therapy.

108 Bevacizumab and the antimetabolites capecitabine and gemcitabine have been s

109 While most antimetabolites caused a cytostatic effect on cell growt

110 When challenged with both DNA damaging and antimetabolite chemotherapeutics, RB was required for pr

111 Antimetabolite chemotherapy exposure was associated with

112 ses remains extremely poor despite high-dose antimetabolite chemotherapy.

113 AcAS as the target of the MMV693183-derived antimetabolite, CoA-MMV693183.

114 Standard (non-antimetabolite) combination chemotherapy administered pa

115 These findings suggest that antimetabolites could improve overall patient well-being

116 Likely causes include the use of antimetabolites, cyclodestructive procedures, and chroni

117 Antimetabolites (cytarabine) may lead to a degeneration

118 the same treatment or switched to the other antimetabolite, depending on their 6-month outcome.

119 used in oncology for decades, dating back to antimetabolites developed in the 1940s.

120 cosatetraenoate, did not mimic AA, and an AA antimetabolite did not block responses to AA.

121 previously undergone trabeculectomy without antimetabolites, divided into two groups.

122 The association between antimetabolite dose intensity (DI) and adverse events am

123 iazol-2-yl)-3,4-dihydroxybenzamide], a novel antimetabolite drug developed at City of Hope Cancer Cen

124 esent another critical mechanism of acquired antimetabolite drug resistance in relapsed childhood ALL

125 The antimetabolite drug, 5-fluorouracil, inhibits microbial

126 The use and type of antimetabolite drugs had no affect on recurrence.

127 Antimetabolite drugs such as gemcitabine and 5-fluoroura

128 endogenous pyrimidines and pyrimidine-based antimetabolite drugs.

129 sorption and its metabolism, and exposure to antimetabolite drugs.

130 mediate bacterial resistance to sulfonamide antimetabolite drugs.

131 Following the withdrawal of the antimetabolite due to the persistent CMV DNAemia and lym

132 d the effects of 5-fluorouracil (5-FUra), an antimetabolite effective against colon tumors, on nitric

133 nosuppression management was to withdraw the antimetabolite first (73%), while only 12% responded the

134 Antimetabolites, first used to treat patients in the ear

135 Therapeutic applications include antimetabolites for modulation of proliferative vitreore

136 ential growth of Huh-7 cells, the effects of antimetabolites for several nucleoside biosynthesis path

137 The mechanisms of resistance to the antimetabolite gemcitabine in non-small cell lung cancer

138 one via melt-polymerization, with the active antimetabolite GMT, thus, becoming the repeat unit that

139 2 months, approximately half of eyes in each antimetabolite group still had persistent macular edema.

140 We used bioinformatics, antimetabolite growth assays, RT-qPCR, targeted mutagene

141 Radiosensitization with antimetabolites has improved clinical outcome for patien

142 edical treatments with systemic steroids and antimetabolites have been tried but with variable result

143 Although anti-inflammatories and antimetabolites have been used with success, these nonsp

144 phacoemulsification and trabeculectomy with antimetabolites have vastly improved the results of comb

145 typically involving intrathecal or high-dose antimetabolites, have been developed in the front-line t

146 bined with a calcineurin inhibitor (CNI) and antimetabolite (hazard ratio [HR] 0.73 versus no inducti

147 Antimetabolites (HR = 0.91; 95% CI 0.84-0.97) and molecu

148 Azathioprine, a purine antimetabolite immunosuppressant, photosensitizes the sk

149 lead to drug discontinuation or reduction in antimetabolite immunosuppression.

150 pathways involved in radiosensitization with antimetabolites implicate base excision repair with the

151 -Fluorouracil (5-FU) is the most widely used antimetabolite in the treatment of colorectal, breast an

152 in patients treated with corticosteroids and antimetabolites in a sex-specific manner.

153 nhibitors, but also enhances the toxicity of antimetabolites in cancer cell lines.

154 action with taxanes, anthracyclines and some antimetabolites in HER-2/neu-overexpressing breast cance

155 se (FPGS) catalyzes the activation of folate antimetabolites in mammalian tissues and tumors.

156 he major publications relating to the use of antimetabolites in ocular surface neoplasia and highligh

157 n encouraging experiences with high doses of antimetabolites in primary CNS lymphoma and with rituxim

158 they are also resistant to a number of other antimetabolites in the DNA synthesis pathway in a TNFalp

159 K ineffective in generating CoA analogues as antimetabolites in vivo.

160 est and irregular cellular morphologies, the antimetabolite-induced arrest was highly reversible and

161 The antimetabolite-induced p53-dependent arrest response was

162 -fluorouracil), which acts at early steps of antimetabolite-induced stress by stimulating phosphoryla

163 tations that impart resistance to pyrimidine antimetabolite inhibitors also relieve CTP inhibition an

164 Modeling these antimetabolites into the pantothenate active site predic

165 lysine (Lys) and resistance to the toxic Lys antimetabolite, L-thialysine (Thl) in Escherichia coli.

166 enylate kinase isoenzyme 1 (AK1) inactivates antimetabolites like Cytarabine.

167 The antimetabolite methotrexate (MTX) was inferred recently

168 Moreover, the antimetabolite methotrexate synergizes with TH5487 throu

169 ione (DNP-SG) and leukotriene C4 (LTC4), the antimetabolite methotrexate, and the bile acid glycochol

170 nfer greater benefits when combined with the antimetabolite methotrexate.

171 ely 1.7-fold resistance was observed for the antimetabolite methotrexate.

172 monly used immunosuppressants-especially the antimetabolites methotrexate, mycophenolate mofetil, and

173 tly infliximab, adalimumab, and etanercept); antimetabolites (methotrexate, mycophenolate mofetil, az

174 of HBL100 cells treated with 5-fluorouracil (antimetabolite), methotrexate (antimetabolite), tamoxife

175 suppression (ECI), with a TNF antagonist and antimetabolite might be a more effective strategy.

176 The intraoperative use of the antimetabolites mitomycin C and 5-fluorouracil in both t

177 y to childhood glaucoma-including the use of antimetabolites, modern glaucoma drainage devices, and t

178 inhibitors of calcium-dependent pathways and antimetabolites, modulators of T-cell costimulation are

179 andard-dose cyclosporin or tacrolimus and an antimetabolite, mostly mycophenolate mofetil (91.7%).

180 tions of cyclosporine and those treated with antimetabolites (mycophenolate and azathioprine) have a

181 The pantothenic acid antimetabolite N-heptylpantothenamide (N7-Pan) possesses

182 The pantothenic acid antimetabolite N-pentylpantothenamide inhibits the growt

183 ction of p53 and associated G1 arrest by the antimetabolite, N-(phosphonoacetyl)-L-aspartate (PALA),

184 n Experiment 2, rats injected with the lipid antimetabolite Na-2-mercaptoacetate (MA) responded more

185 is an unusual deoxy-sugar, which acts as an antimetabolite of the shikimate pathway, thereby exhibit

186 The benefit of CNI plus antimetabolite on patient and graft survival increased w

187 ho have failed or who are not candidates for antimetabolite or calcineurin inhibitor immunomodulation

188 eotide metabolism-and thus interact with the antimetabolite or radiation intervention.

189 oach, when the immunosuppressive agents were antimetabolites or calcineurin inhibitors.

190 on at 12 months compared with treatment with antimetabolites or calcineurin inhibitors.

191 inimum of 20 mg of prednisone, cyclosporine, antimetabolites, or any combination of these agents were

192 The antimetabolite prodrug 3-deazauridine (3DUrd) inhibits C

193 munosuppressive armamentarium, replacing the antimetabolite prodrug azathioprine, reports have associ

194 no acids have long been recognized for their antimetabolite properties and tendency to be uncovered t

195 The combination of high doses of antimetabolites, R-HDS, and ASCT is feasible and effecti

196 The antimetabolite radiosensitizers may inhibit thymidylate

197 Refinement of existing antimetabolite regimens can improve surgical results, es

198 ombination of a calcineurin inhibitor and an antimetabolite remains standard care for graft-versus-ho

199 Treatment with antimetabolites results in chemically induced low nucleo

200 ocedure, phacoemulsification-trabeculectomy, antimetabolites, results and complications, as well as c

201 Additionally, many surgeons are employing antimetabolites routinely in combined phacoemulsificatio

202 s of riboswitches serves as a target for the antimetabolite S-(2-aminoethyl)-L-cysteine (AEC).

203 ould probably not be tested further, but its antimetabolite schedules and frequent drug administratio

204 results suggest that chlorambucil and/or an antimetabolite should be administered before cyclophosph

205 However, the antimetabolites still have many potential problems and s

206 l pathways has allowed the emergence of new 'antimetabolite' strategies to increase the therapeutic e

207 Pegargiminase-based chemotherapy as a novel antimetabolite strategy for mesothelioma validates wider

208 ent approach, we identified a novel targeted antimetabolite strategy to exploit arginine deprivation

209 Purine nucleoside antimetabolites, such as clofarabine, are effective anti

210 The antimetabolites, such as methotrexate, azathioprine, lef

211 Antimetabolites, such as the DNA-hypomethylating agent 5

212 ence shows that second-line agents including antimetabolites, T-cell inhibitors and alkylating agents

213 Immunosuppressed patients were treated with antimetabolites, T-cell inhibitors, and/or alkylating ag

214 fluorouracil (antimetabolite), methotrexate (antimetabolite), tamoxifen (antiestrogen/antiproliferati

215 d trabeculectomy with releasable sutures and antimetabolites, techniques have improved considerably i

216 Pemetrexed (ALIMTA, Lilly) is a folate antimetabolite that has been approved by the U.S. Food a

217 Mitomycin-C is an antimetabolite that has seen increased use in ophthalmol

218 5-Fluorouracil (5-FU) is an antineoplastic antimetabolite that is widely administered to cancer pat

219 Nucleoside analogs are structurally similar antimetabolites that have a broad range of action and ar

220 y when used in combination with conventional antimetabolites that reduce "bulk" tumor size.

221 a suitable companion biomarker for targeted antimetabolite therapies in human breast cancers.

222 nflammatory bowel disease (IBD), who were on antimetabolite therapy (azathioprine or methotrexate), T

223 ur work suggests the potential use of NAD(H) antimetabolite therapy against the viral infection.

224 study, we assessed the effects of an intense antimetabolite therapy alternating with APO on overall s

225 s with T-cell ALL treated with standard-dose antimetabolite therapy and implies that higher-dose meth

226 he targeted delivery of combined sonodynamic/antimetabolite therapy in pancreatic cancer.

227 s protocols, in that more intensive systemic antimetabolite therapy was given before and during radio

228 tation in DHFS prevents the formation of the antimetabolite, thereby conferring resistance to PAS.

229 in vivo LysO exports the naturally occurring antimetabolite Thl with higher affinity over the essenti

230 ficacy and safety of the conversion from the antimetabolite to an mTORi for the prevention of CMV rec

231 ndings highlight the potential use of NAD(H) antimetabolites to counter ZIKV infection and pathogenes

232 The antifolates were the first class of antimetabolites to enter the clinics more than 50 years

233 eated with 2 of the most commonly prescribed antimetabolite treatments.

234 The class of folate antimetabolites typified by (6R)-dideazatetrahydrofolate

235 us (pOR, 0.66 [95% CI, 0.53-0.83]; I2 = 0%), antimetabolite use (pOR, 0.21 [95% CI, 0.14-0.29]; I2 =

236 reless incisions, filtration procedures, and antimetabolite use are studied.

237 ts who underwent transplantation after 2000, antimetabolite use at 1 year was associated with improve

238 was a higher mean drug level with concurrent antimetabolite use compared with monotherapy (mean [SD],

239 and ADAs, clinical response, and concurrent antimetabolite use in patients treated with TNFis for NI

240 5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal

241 Cytarabine arabinoside (ara-C) is an antimetabolite used to treat hematologic malignancies.

242 CNI plus antimetabolite was associated with improved adjusted pat

243 presentation compared to the first patient, antimetabolite was discontinued and only hydroxychloroqu

244 has included a calcineurin inhibitor plus an antimetabolite, whereas treatment has relied mainly on c

245 (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic ac

246 cause marked resistance to tetrahydrofolate antimetabolites, while still allowing cell survival.

247 ntensity than CAF and improved scheduling of antimetabolites with sequential methotrexate and 5-FU, a

248 Therapeutic management included antimetabolite withdrawal (68%), calcineurin inhibitor w

249 munosuppressants included discontinuation of antimetabolites without changes in calcineurin inhibitor